Search results for "RICS"

showing 10 items of 14086 documents

Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders.

2018

Objective: To evaluate effects of autologous stem cell ovarian transplant (ASCOT) on ovarian reserve and IVF outcomes of women who arc poor responders with very poor prognosis. Design: Prospective observational pilot study. Setting: University hospital. Patient(s): Seventeen women who are poor responders. Intervention(s): Ovarian infusion of bone marrow-derived stem cells. Main Outcome Measure(s): Serum antimullerian hormone levels and antral follicular count (AFC), punctured follicles, and oocytes retrieved after stimulation (controlled ovarian stimulation) were measred. Apheresis was analyzed for growth factor concentrations. Result(s): The ASCOT resulted in a significant improvement in A…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPoor responderPilot ProjectsFertilization in VitroTransplantation Autologousovarian reserve03 medical and health sciencesFollicle0302 clinical medicinebone marrow-derived stem cell transplantInternal medicineFollicular phasemedicineAMHHumansProspective StudiesOvarian reserveOvarian ReservePregnancy030219 obstetrics & reproductive medicinebusiness.industryReproductionOvaryObstetrics and Gynecologymedicine.diseaseAntral follicleOocyteClinical trial030104 developmental biologymedicine.anatomical_structureTreatment OutcomeReproductive Medicineantral follicular countFemaleStem cellbusinessInfertility FemaleStem Cell TransplantationFertility and sterility
researchProduct

M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients

2021

Objective. Despite radical surgery and chemotherapy, most patients with ovarian cancer die due to disease progression. M-Trap is an implantable medical device designed to capture peritoneal disseminated tumor cells with the aim to focalize the disease. This trial analyzed the safety and performance of the device. Methods. This first-in-human prospective, multi-center, non-blinded, single-arm study enrolled 23 women with high-grade serous advanced ovarian cancer. After primary or interval debulking surgery, 3 M-Trap devices were placed in the peritoneum of the abdominal cavity. 18-months post-implantation or at disease progression, devices were initially removed by laparoscopy. The primary s…

0301 basic medicineOncologyAdultmedicine.medical_specialtymedicine.medical_treatmentPerformanceDiseaseCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansCytoreductive surgeryProspective StudiesRadical surgeryNeoplasm MetastasisAdverse effectLaparoscopyPeritoneal NeoplasmsAgedOvarian NeoplasmsChemotherapymedicine.diagnostic_testbusiness.industryM-Trap deviceObstetrics and GynecologyCytoreduction Surgical ProceduresMiddle AgedDebulkingmedicine.diseaseSerous fluid030104 developmental biologyTreatment OutcomeOncologySpain030220 oncology & carcinogenesisAdvanced ovarian cancerFemaleNeoplasm Recurrence LocalRecurrent ovarian cancerSafetyOvarian cancerbusinessPeritoneal carcinomatosis
researchProduct

Análisis de biopsias líquidas para el diagnóstico del cáncer: revisión sistemática

2020

The incidence of cancer has increased in recent years, especially in those over 65 years of age, posing a major health problem. Many tumours have a poor prognosis because they are diagnosed at very advanced stages. It is therefore especially important to incorporate liquid biopsy into clinical practice as a method for detecting tumours at very early stages. A systematic review was conducted, with the main objective of analysing the available literature on the use of liquid biopsy in the early diagnosis of cancer, and as a secondary objective, to determine the types of tumours that can be diagnosed early by liquid biopsy and the available biomarkers. The results indicate a lack of agreement …

0301 basic medicineOncologyAgingmedicine.medical_specialtyPoor prognosisScreening testbusiness.industryIncidence (epidemiology)Advanced stageMedicine (miscellaneous)Cancermedicine.diseaseClinical Practice03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemedicineGeriatrics and GerontologyLiquid biopsybusinessRevista Española de Geriatría y Gerontología
researchProduct

Circulating Molecular Chaperones in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: Data from the Zabùt Aging Project

2022

Molecular chaperones play essential roles in many processes such as cell differentiation, tissue homeostasis, and organ remodeling. Recent data indicate that chaperones can act as cytoprotectants for brain cells during the progression of neurodegenerative diseases, including Alzheimer’s disease (AD). However, very few data on the levels of chaperones in dementia, including its prodromal phases, have been reported. In this study, we used biological samples and epidemiological data collected during the Zabùt Aging Project (a prospective, community-based, cohort study of normal/pathological aging conducted in Sicily, Italy, with a follow-up of ten years) to determine if there is an association…

0301 basic medicineOncologyAgingmedicine.medical_specialtySettore MED/09 - Medicina InternaHsp90DiseaseNeuropsychological Testsmedicine.disease_causeHsp70Cohort Studies03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineEpidemiologyoxidative stressHumansMedicineDementiaCognitive DysfunctionProspective StudiesPathologicalTissue homeostasiscognitive impairmentSettore MED/04 - Patologia Generalebusiness.industryGeneral NeuroscienceNeurodegenerationneurodegenerationGeneral Medicinemolecular chaperoneHsp60medicine.diseasePsychiatry and Mental healthClinical Psychology030104 developmental biologySettore MED/26 - NeurologiaGeriatrics and GerontologybusinessAlzheimer’s disease030217 neurology & neurosurgeryOxidative stressMolecular ChaperonesCohort studyJournal of Alzheimer's Disease
researchProduct

Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome

2017

// Mariona Jove 1, * , Irene Pradas 1, * , Alba Naudi 1, * , Susana Rovira-Llopis 2 , Celia Banuls 2 , Milagros Rocha 2 , Manuel Portero-Otin 1 , Antonio Hernandez-Mijares 2, 3, 4, # , Victor M. Victor 2, 5, # and Reinald Pamplona 1, # 1 Department of Experimental Medicine, Lleida University-Institute for Research in Biomedicine of Lleida (UdL-IRBLleida), 25198 Lleida, Spain 2 Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Service of Endocrinology, University Hospital Dr. Peset, 46017 Valencia, Spain 3 Fundacion Investigacion Hospital Clinico Universitario/INCLIVA, Valencia University, 46010 Valencia, Spain 4 Department of Medicine, …

0301 basic medicineOncologyCell signaling moleculesmedicine.medical_specialtyCell signalingGlycerophospholipidsDiseaseGlycerophospholipidsFree fatty acidsValencian community03 medical and health sciences0302 clinical medicineInternal medicineLipidomicsmedicinelipid de novo biosynthesisglycerophospholipids030219 obstetrics & reproductive medicinebusiness.industryfree fatty acidsLipidomeUniversity hospitalPolycystic ovary030104 developmental biologyOncologyLipidomicscell signaling moleculeslipidomicsbusinessResearch PaperOncotarget
researchProduct

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.

2017

Abstract Purpose The prognosis is poor for patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC). Evidence suggests that antiangiogenic treatment modalities could play a major role in EOC. A combined therapy consisting of the investigational oral antiangiogenic agent pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, previously treated EOC. Patients and methods This study was designed as a multicenter phase I trial evaluating the optimal dose as well as activity and tolerability of pazopanib with metronomic cyclophosphamide in the treatment of patients with recurrent, platinum-resistant, previously tre…

0301 basic medicineOncologyDiarrheamedicine.medical_specialtyIndazolesCyclophosphamideMaximum Tolerated DosePlatinum CompoundsCarcinoma Ovarian EpithelialDisease-Free SurvivalPazopanib03 medical and health sciences0302 clinical medicineLiver Function TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasms Glandular and EpithelialAdverse effectCyclophosphamideFatigueAgedOvarian NeoplasmsSulfonamidesLeukopeniabusiness.industryObstetrics and GynecologyLeukopeniaMiddle Agedmedicine.diseaseSurgeryRegimen030104 developmental biologyPyrimidinesOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisFallopian tube cancerFemalemedicine.symptomNeoplasm GradingNeoplasm Recurrence LocalbusinessOvarian cancerNeoplasms Cystic Mucinous and Serousmedicine.drugGynecologic oncology
researchProduct

Red Blood Cell Distribution Width, Vascular Aging Biomarkers, and Endothelial Progenitor Cells for Predicting Vascular Aging and Diagnosing/Prognosin…

2018

The emerging evidence emphasizes Red blood cell distribution width (RDW) as optimal prognostic biomarker for cardiovascular diseases. However, several clinical biases impede its clinical application. Recent recommendations suggest combining RDW with other biomarkers. Accordingly, we propose evaluating the well-recognized biomarkers of vascular aging (i.e., the leukocyte telomere length and telomerase activity, and reduced levels of endothelial progenitor cells [EPCs]) with RDW, for predicting the risk for vascular aging and onset and prognosis of age-related degenerative arterial diseases, such as sporadic ascending aorta aneurysm (AAA), characterized to have an increased incidence in old p…

0301 basic medicineOncologyErythrocyte IndicesMaleTelomeraseAgingEPCs; RDW; diagnostic and prognostic AAA biomarkers; leukocyte telomere length; risk for vascular aging and sporadic AAA; telomere activityArterial diseaserisk for vascular aging and sporadic AAA0302 clinical medicineRisk FactorsLeukocytesMedicinetelomere activityEndothelial Progenitor CellsAged 80 and overMiddle AgedTelomerePrognosisAortic AneurysmC-Reactive Proteincardiovascular systemBiomarker (medicine)Vascular agingFemaleAdultmedicine.medical_specialtydiagnostic and prognostic AAA biomarkersleukocyte telomere length03 medical and health sciencesYoung AdultInternal medicinemedicine.arterySettore MED/05 - Patologia ClinicaRDWHumansVascular DiseasesProgenitor cellAgedAortabusiness.industrySettore MED/23 - Chirurgia CardiacaRed blood cell distribution widthEPCTelomere030104 developmental biologyCase-Control StudiesEPCsGeriatrics and Gerontologybusinessdiagnostic and prognostic AAA biomarker030217 neurology & neurosurgeryBiomarkersRejuvenation research
researchProduct

Oxidative stress and frailty : a systematic review and synthesis of the best evidence

2017

Objective Oxidative stress (OS) is associated with accelerated aging. Previous studies have suggested a possible relationship between OS and frailty but this association remains unclear. We conducted a systematic review to investigate potential interactions between OS and frailty. Methods A systematic literature search of original reports providing data on ‘OS and antioxidant’ parameters and frailty was carried out across major electronic databases from inception until May 2016. Cross-sectional/case control and longitudinal studies reporting data on the association between frailty and anti-oxidants-OS biomarkers were considered for inclusion. Results were summarized with a synthesis based o…

0301 basic medicineOncologyGerontologyGenetics and Molecular Biology (all)AgingCross-sectional studyalpha-TocopherolAntioxidantesIsoprostanesmedicine.disease_causeBiochemistryAnti-oxidantAntioxidants0302 clinical medicineLongitudinal StudiesAged 80 and overFrailtyGlutathione DisulfideObstetrics and GynecologyGlutathione8-Hydroxy-2'-DeoxyguanosineSystematic searchAnti-oxidant; Frail; Frailty; Oxidative stress; Biochemistry Genetics and Molecular Biology (all); Obstetrics and Gynecologymedicine.medical_specialtyFrail ElderlyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesFrailInternal medicinemedicineHumansFrail elderlySulfhydryl CompoundsAgedAldehydesbusiness.industryCase-control studyFrailty Frail Oxidative stress Anti-oxidantEstresse OxidativoDeoxyguanosineMean ageOxidized GlutathioneOxidative Stress030104 developmental biologyCross-Sectional Studies1-Alkyl-2-acetylglycerophosphocholine EsteraseBest evidencebusinessReactive Oxygen Species030217 neurology & neurosurgeryOxidative stressBiomarkers
researchProduct

EGFR inhibition in NSCLC: New findings…. and opened questions?

2017

The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent f…

0301 basic medicineOncologyLung Neoplasmsmedicine.medical_treatmentAfatinibResistanceTreatment of lung cancerTargeted therapyTargeted therapyAntineoplastic Agent0302 clinical medicineEpidermal growth factorEpidermal growth factor receptorMolecular Targeted TherapybiologyHematologyTKIErbB ReceptorsOncology030220 oncology & carcinogenesisErlotinibReceptorHumanmedicine.drugmedicine.medical_specialtyEGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor Epidermal Growth Factor; Hematology; Oncology; Geriatrics and GerontologyEGFRProtein Kinase InhibitorAntineoplastic Agents03 medical and health sciencesGefitinibInternal medicinemedicineHumansLiquid biopsyIntensive care medicineProtein Kinase InhibitorsEGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor; Epidermal Growth Factor; Hematology; Oncology; Geriatrics and GerontologyEpidermal Growth FactorLiquid biopsybusiness.industryrespiratory tract diseasesLung Neoplasm030104 developmental biologyTKIsMutationbiology.proteinReceptor Epidermal Growth FactorGeriatrics and Gerontologybusiness
researchProduct

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

2019

Lymph node ratio (LNR) can predict treatment outcome and prognosis in patients with solid tumors. Aim of the present analysis was to confirm the concept of using LNR for assessing outcome in patients with vulvar cancer after surgery with inguinal lymphadenectomy in a large multicenter project.The AGO-CaRE-1 study multicenter database was used for analysis. LNR was defined as ratio of number of positive lymph nodes (LN) to the number of resected. Previously established LNR risk groups were used to stratify patients. LNR was investigated with respect to clinical parameters. Univariate and multivariable survival analyses were performed to assess the value of LNR in order to predict overall (OS…

0301 basic medicineOncologyMalemedicine.medical_specialtyMedizinInguinal lymphadenectomyRisk AssessmentVulva03 medical and health sciences0302 clinical medicineRisk groupsPredictive Value of TestsInternal medicineNodal statusGermanymedicineHumansIn patientLymph nodeAgedNeoplasm StagingRetrospective StudiesVulvar Neoplasmsbusiness.industryObstetrics and GynecologyVulvar cancerMiddle Agedmedicine.diseasePrognosisSurvival Analysis030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous CellLymph Node ExcisionFemaleLymphLymph NodesbusinessGynecologic oncology
researchProduct